Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

osimertinib 3 Vinorelbine 3 Pemetrexed 3 Cisplatin 3 Carboplatin 3 Gemcitabine 2 Gefitinib 2 Docetaxel 2 CP protocol 2 rezivertinib 1 pembrolizumab 1 aumolertinib 1 Taxes 1 Paclitaxel 1 HMPL-013 1 HM781-36B 1 Erlotinib Hydrochloride 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × NSCLC × HM781-36B × Clear all

NCT05378763 2026-05-22

PINNACLE

Spectrum Pharmaceuticals, Inc

Phase 3 Suspended

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡